卫信康：子公司获得药物临床试验批准通知书

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tibet Zhongwei Chengkang, has received approval from the National Medical Products Administration for the clinical trial of Lidocaine and Bupivacaine Cream, which is a significant development for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Development - The Lidocaine and Bupivacaine Cream was developed by Zars Company and received FDA approval in the United States on June 29, 2006, under the brand name Pliaglis [1] - The cream contains 70mg of Lidocaine and 70mg of Bupivacaine per gram [1] - Currently, there are no domestic listings for this product in China [1] Group 2: Regulatory Approval - The National Medical Products Administration has included the Lidocaine and Bupivacaine Cream in the 31st batch of reference preparation directory, confirming its status as a reference preparation for unimported original drugs listed in the US Orange Book and the EU [1] - The licensed manufacturers for the reference preparation are Taro Pharmaceuticals and Difa Cooper SPA/Galderma Laboratorium GmbH [1]